Our findings suggest that targeting TLR4‐IRE1α pathway can be a potential therapeutic choice for the treatment of NAFLD as well as other metabolic disorders, with lipotoxicity being the principal pathomechanism. The gene discussed is ERN1; the disease is metabolic dysfunction-associated steatotic liver disease.